Neisseria gonorrhoeae Infections - Pipeline Review, H2 2016

Global Markets Direct’s, ‘Neisseria gonorrhoeae Infections - Pipeline Review, H2 2016’, provides an overview of the Neisseria gonorrhoeae Infections pipeline landscape.

The report provides comprehensive information on the therapeutics under development for Neisseria gonorrhoeae Infections, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for Neisseria gonorrhoeae Infections and features dormant and discontinued projects.

Global Markets Direct’s report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Note: Certain sections in the report may be removed or altered based on the availability and relevance of data.

Scope

The report provides a snapshot of the global therapeutic landscape of Neisseria gonorrhoeae Infections

The report reviews pipeline therapeutics for Neisseria gonorrhoeae Infections by companies and universities/research institutes based on information derived from company and industry-specific sources

The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages

The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities

The report reviews key players involved Neisseria gonorrhoeae Infections therapeutics and enlists all their major and minor projects

The report assesses Neisseria gonorrhoeae Infections therapeutics based on drug target, mechanism of action (MoA), route of administration (RoA) and molecule type

The report summarizes all the dormant and discontinued pipeline projects

The report reviews latest news related to pipeline therapeutics for Neisseria gonorrhoeae Infections

Reasons to buy

Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies

Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage

Identify and understand important and diverse types of therapeutics under development for Neisseria gonorrhoeae Infections

Identify potential new clients or partners in the target demographic

Develop strategic initiatives by understanding the focus areas of leading companies

Plan mergers and acquisitions effectively by identifying key players and it’s most promising pipeline therapeutics

Devise corrective measures for pipeline projects by understanding Neisseria gonorrhoeae Infections pipeline depth and focus of Indication therapeutics

Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope

Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline

Companies mentioned

Allergan Plc

BioDiem Ltd

Biolytics Pharma

Debiopharm International SA

F. Hoffmann-La Roche Ltd.

GlaxoSmithKline Plc

Merck & Co., Inc.

Paratek Pharmaceuticals, Inc.

Recce Pty Ltd ...

Allergan Plc

BioDiem Ltd

Biolytics Pharma

Debiopharm International SA

F. Hoffmann-La Roche Ltd.

GlaxoSmithKline Plc

Merck & Co., Inc.

Paratek Pharmaceuticals, Inc.

Recce Pty Ltd

Redx Pharma Plc

Sarepta Therapeutics, Inc.

Sumitomo Dainippon Pharma Co., Ltd.

Table of Contents

Table of Contents

Table of Contents 2

List of Tables 5

List of Figures 6

Introduction 7

Global Markets Direct Report Coverage 7

Neisseria gonorrhoeae ...

Table of Contents

Table of Contents 2

List of Tables 5

List of Figures 6

Introduction 7

Global Markets Direct Report Coverage 7

Neisseria gonorrhoeae Infections Overview 8

Therapeutics Development 9

Pipeline Products for Neisseria gonorrhoeae Infections - Overview 9

Pipeline Products for Neisseria gonorrhoeae Infections - Comparative Analysis 10

Neisseria gonorrhoeae Infections - Therapeutics under Development by Companies 11

Neisseria gonorrhoeae Infections - Therapeutics under Investigation by Universities/Institutes 12

Neisseria gonorrhoeae Infections - Pipeline Products Glance 13

Late Stage Products 13

Clinical Stage Products 14

Early Stage Products 15

Neisseria gonorrhoeae Infections - Products under Development by Companies 16

Neisseria gonorrhoeae Infections - Products under Investigation by Universities/Institutes 17

Neisseria gonorrhoeae Infections - Companies Involved in Therapeutics Development 18

Allergan Plc 18

BioDiem Ltd 19

Biolytics Pharma 20

Debiopharm International SA 21

F. Hoffmann-La Roche Ltd. 22

GlaxoSmithKline Plc 23

Merck & Co., Inc. 24

Paratek Pharmaceuticals, Inc. 25

Recce Pty Ltd 26

Redx Pharma Plc 27

Sarepta Therapeutics, Inc. 28

Sumitomo Dainippon Pharma Co., Ltd. 29

Neisseria gonorrhoeae Infections - Therapeutics Assessment 30

Assessment by Monotherapy Products 30

Assessment by Target 31

Assessment by Mechanism of Action 33

Assessment by Route of Administration 35

Assessment by Molecule Type 37

Drug Profiles 39

Antisense Oligonucleotide for Drug Resistant Neisseria Gonorrhoeae Infections - Drug Profile 39

Product Description 39

Mechanism Of Action 39

R&D Progress 39

BDM-I - Drug Profile 40

Product Description 40

Mechanism Of Action 40

R&D Progress 40

Biologic for Neisseria Gonorrhoeae Infection - Drug Profile 42

Product Description 42

Mechanism Of Action 42

R&D Progress 42

dalbavancin - Drug Profile 43

Product Description 43

Mechanism Of Action 43

R&D Progress 43

Debio-1453 - Drug Profile 53

Product Description 53

Mechanism Of Action 53

R&D Progress 53

edodekin alfa SR - Drug Profile 54

Product Description 54

Mechanism Of Action 54

R&D Progress 54

gepotidacin mesylate - Drug Profile 55

Product Description 55

Mechanism Of Action 55

R&D Progress 55

Neisseria gonorrhoeae (virus like particle) vaccine - Drug Profile 57

Product Description 57

Mechanism Of Action 57

R&D Progress 57

Neisseria gonorrhoeae vaccine - Drug Profile 58

Product Description 58

Mechanism Of Action 58

R&D Progress 58

omadacycline tosylate - Drug Profile 59

Product Description 59

Mechanism Of Action 59

R&D Progress 59

Recombinant Protein for Neisseria gonorrhoeae Infections - Drug Profile 65

Product Description 65

Mechanism Of Action 65

R&D Progress 65

SM-295291 - Drug Profile 66

Product Description 66

Mechanism Of Action 66

R&D Progress 66

SM-369926 - Drug Profile 67

Product Description 67

Mechanism Of Action 67

R&D Progress 67

Small Molecule to Target Bacterial Cell Wall for Gonorrhoea and Tuberculosis - Drug Profile 68

Product Description 68

Mechanism Of Action 68

R&D Progress 68

Small Molecules for Multi-Drug Resistant Gram-Positive and Gram-Negative Bacterial Infections - Drug Profile 69

Product Description 69

Mechanism Of Action 69

R&D Progress 69

Small Molecules to Inhibit DNA Gyrase for Neisseria Gonorrhoeae Infections - Drug Profile 70

Product Description 70

Mechanism Of Action 70

R&D Progress 70

Small Molecules to Inhibit PBP2 for Neisseria Gonorrhoeae Infections - Drug Profile 71

Product Description 71

Mechanism Of Action 71

R&D Progress 71

Small Molecules to Inhibit Tubulin for Oncology and Neisseria Gonorrhoeae Infections - Drug Profile 72

Product Description 72

Mechanism Of Action 72

R&D Progress 72

solithromycin - Drug Profile 73

Product Description 73

Mechanism Of Action 73

R&D Progress 73

VT-12008911 - Drug Profile 85

Product Description 85

Mechanism Of Action 85

R&D Progress 85

Neisseria gonorrhoeae Infections - Dormant Projects 86

Neisseria gonorrhoeae Infections - Discontinued Products 87

Neisseria gonorrhoeae Infections - Product Development Milestones 88

Featured News & Press Releases 88

Dec 22, 2015: Cempra Enters Into a CRADA With the NIAID and Expands the Phase 3 Solithromycin Clinical Trial in Urogenital Gonorrhea to Include Additional Female Patients and Adolescents 88

Sep 10, 2015: Cempra to Present Data From Antibiotic Drug Solithromycin at ICAAC/ICC 2015 Meeting 88

Nov 19, 2014: Cempra to Receive BARDA Funding for 1b and Start-Up of Phase 2/3 Solithromycin Pediatric Studies 90

Sep 09, 2014: Durata Therapeutics Presented Data at the 54th Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC) 90

Aug 12, 2014: Cempra Initiates Phase 3 Clinical Trial in Patients With Uncomplicated Gonorrhea Infection 92

Apr 26, 2013: Cempra To Present Data On Solithromycin's Potential Against Urogenital Infections And Multidrug-Resistant Pathogens At ECCMID 92

Aug 08, 2012: BioDiem Receives European Patent For Antimicrobial Compound BDM-I 94

Mar 31, 2012: Cempra's Solithromycin Demonstrates In Vitro Activity Against Antibiotic-Resistant Neisseria Gonorrhoeae Isolates 94

Appendix 97

Methodology 97

Coverage 97

Secondary Research 97

Primary Research 97

Expert Panel Validation 97

Contact Us 97

Disclaimer 98

List of Tables

List of Tables

Number of Products under Development for Neisseria gonorrhoeae Infections, H2 2016 9

Number of Products under Development for Neisseria gonorrhoeae Infections - ...

List of Tables

Number of Products under Development for Neisseria gonorrhoeae Infections, H2 2016 9

Number of Products under Development for Neisseria gonorrhoeae Infections - Comparative Analysis, H2 2016 10

Number of Products under Development by Companies, H2 2016 11

Number of Products under Investigation by Universities/Institutes, H2 2016 12

Comparative Analysis by Late Stage Development, H2 2016 13

Comparative Analysis by Clinical Stage Development, H2 2016 14

Comparative Analysis by Early Stage Development, H2 2016 15

Products under Development by Companies, H2 2016 16

Products under Investigation by Universities/Institutes, H2 2016 17

Neisseria gonorrhoeae Infections - Pipeline by Allergan Plc, H2 2016 18

Neisseria gonorrhoeae Infections - Pipeline by BioDiem Ltd, H2 2016 19

Neisseria gonorrhoeae Infections - Pipeline by Biolytics Pharma, H2 2016 20

Neisseria gonorrhoeae Infections - Pipeline by Debiopharm International SA , H2 2016 21

Neisseria gonorrhoeae Infections - Pipeline by F. Hoffmann-La Roche Ltd., H2 2016 22

Neisseria gonorrhoeae Infections - Pipeline by GlaxoSmithKline Plc, H2 2016 23

Neisseria gonorrhoeae Infections - Pipeline by Merck & Co., Inc., H2 2016 24

Neisseria gonorrhoeae Infections - Pipeline by Paratek Pharmaceuticals, Inc., H2 2016 25

Neisseria gonorrhoeae Infections - Pipeline by Recce Pty Ltd, H2 2016 26

Neisseria gonorrhoeae Infections - Pipeline by Redx Pharma Plc, H2 2016 27

Neisseria gonorrhoeae Infections - Pipeline by Sarepta Therapeutics, Inc., H2 2016 28

Neisseria gonorrhoeae Infections - Pipeline by Sumitomo Dainippon Pharma Co., Ltd., H2 2016 29

Assessment by Monotherapy Products, H2 2016 30

Number of Products by Stage and Target, H2 2016 32

Number of Products by Stage and Mechanism of Action, H2 2016 34

Number of Products by Stage and Route of Administration, H2 2016 36

Number of Products by Stage and Molecule Type, H2 2016 38

Neisseria gonorrhoeae Infections - Dormant Projects, H2 2016 86

Neisseria gonorrhoeae Infections - Discontinued Products, H2 2016 87

List of Figures

List of Figures

Number of Products under Development for Neisseria gonorrhoeae Infections, H2 2016 9

Number of Products under Development for Neisseria gonorrhoeae Infections - ...

List of Figures

Number of Products under Development for Neisseria gonorrhoeae Infections, H2 2016 9

Number of Products under Development for Neisseria gonorrhoeae Infections - Comparative Analysis, H2 2016 10

Number of Products under Development by Companies, H2 2016 11

Number of Products under Investigation by Universities/Institutes, H2 2016 12

Comparative Analysis by Early Stage Products, H2 2016 15

Assessment by Monotherapy Products, H2 2016 30

Number of Products by Top 10 Targets, H2 2016 31

Number of Products by Stage and Top 10 Targets, H2 2016 31

Number of Products by Top 10 Mechanism of Actions, H2 2016 33

Number of Products by Stage and Top 10 Mechanism of Actions, H2 2016 33

Number of Products by Routes of Administration, H2 2016 35

Number of Products by Stage and Routes of Administration, H2 2016 35

Number of Products by Molecule Types, H2 2016 37

Number of Products by Stage and Molecule Types, H2 2016 37

    Pricing

Discounts available for multiple report purchases.

reportstore@globalmarketsdirect.com
+44 (0) 161 359 5414

Saved reports